直腸癌分子診斷市場報告：2031 年趨勢、預測與競爭分析

全球直腸癌分子診斷市場前景光明，得益於臨床診斷、藥物篩檢和監測市場的巨大機會。預計2025年至2031年，全球直腸癌分子診斷市場將以11.5%的複合年成長率成長。該市場的主要驅動力包括直腸癌發病率的上升和對早期檢測的需求，以及個人化醫療和標靶治療方法的日益普及。

• Lucintel 預測，在整個預測期內，DNA 定序仍將是按類型分類的最大細分市場。
• 從應用來看，臨床診斷預計將實現最高的成長。
• 按地區分類，預計亞太地區在預測期內將呈現最高成長。

直腸癌分子診斷市場的新趨勢

直腸癌分子診斷市場正在經歷一些新興趨勢，例如診斷技術的創新、個人化治療方案以及非侵入性檢測方法的進步，這些趨勢正在塑造市場的未來並改善臨床結果。

• 液態切片技術的興起：液態切片正擴大應用於直腸癌的分子診斷。它是一種非侵入性的傳統組織切片檢查替代方法，可以檢測血液樣本中的腫瘤DNA。這項技術可以提高早期檢測率，並有助於監測治療反應，從而更好地管理患者。
• 次世代定序儀(NGS) 的進展：NGS 已成為分子診斷的基石，能夠檢測與直腸癌相關的基因突變和變異。 NGS 能夠進行全面的基因組分析，有助於早期癌症檢測和製定個人化治療策略。
• 個人化醫療日益受到重視：個人化醫療在直腸癌的分子診斷領域發展勢頭強勁。識別基因突變使醫療保健提供者能夠根據患者的個別情況制定個人化治療方案。這種方法確保患者獲得最有效的治療，提高存活率並減少不必要的副作用。
• 人工智慧 (AI) 在診斷中的應用：AI 透過分析大量患者數據（包括基因、組織病理學和影像數據），在直腸癌的分子診斷中發揮關鍵作用。 AI 工具可以檢測出人類臨床醫生可能遺漏的模式，從而提高診斷準確性並提供更準確的預後資訊。
• 照護現場診斷的應用日益廣泛：照護現場日益受到人們的關注，因為它能夠加快分子檢測並更快地獲得結果。這一趨勢在集中式診斷實驗室有限的開發中國家尤其重要。照護現場技術正在幫助提高分子診斷的可近性和及時性。

這些新興趨勢正在改變直腸癌的分子診斷，使其更早、更準確、侵入性更小，為更個人化的治療策略鋪平道路，改善全球患者的臨床結果，並改善直腸癌的整體預後。

直腸癌分子診斷市場的最新趨勢

隨著診斷技術、生物標記和治療策略的進步，直腸癌的分子診斷技術正在迅速發展。這些發展正在提高診斷的準確性，並使得針對個別患者的治療方案能夠個人化。

• 引言：一些關鍵的發展正在塑造直腸癌的分子診斷，包括非侵入性診斷方法的興起、基因組檢測可及性的提高以及人工智慧技術的整合。這些發展正在提高直腸癌的診斷能力和患者照護。
• 非侵入性檢測的進展：液態切片和糞便DNA檢測等非侵入性檢測方法正在迅速發展。這些技術能夠在最大程度上減少患者不適的情況下早期發現直腸癌，為更廣泛的篩檢和監測方案鋪平了道路，尤其是在醫療資源匱乏的人群中。
• 改良的基因組分析技術：使用次世代定序儀(NGS) 進行基因組分析能夠更準確地識別與直腸癌相關的特定突變，從而實現更準確的診斷和個人化治療的開發，改善患者的治療效果。
• 人工智慧在診斷中的應用：人工智慧正被應用於直腸癌的分子診斷，以提高檢測的準確性和效率。人工智慧透過分析基因組數據、病歷和影像學結果，識別早期直腸癌的診斷模式，從而加快干預速度並改善預後。
• 用於早期檢測的新型生物標記：研究人員正在識別直腸癌特異性的新型生物標記物，這些標記有助於提高早期檢測和預後。特定基因突變和循環腫瘤DNA等生物標記有助於確定最有效的治療方法並後續觀察。
• 個人化醫療的發展：個人化醫療在直腸癌診斷中也日益普及。透過分析患者的基因圖譜，臨床醫生可以選擇最合適的治療方法，包括標靶治療，從而改善患者預後，同時最大限度地減少常規治療方法的副作用。

這些關鍵進展正在推動直腸癌的分子診斷技術，使早期發現更加有效，治療更加個人化。隨著這些技術的不斷發展，它們有望顯著改善患者的預後，並徹底改變全球癌症治療。

目錄

第1章執行摘要

第2章 市場概況

• 背景和分類
• 供應鏈

第3章：市場趨勢及預測分析

• 產業驅動力與挑戰
• PESTLE分析
• 專利分析
• 法規環境

第4章直腸癌分子診斷市場（按類型）

• 概述
• 按類型：吸引力分析
• PCR：趨勢與預測（2019-2031）
• FISH：趨勢與預測（2019-2031）
• DNA定序：趨勢與預測（2019-2031）
• 基因晶片：趨勢與預測（2019-2031）

5. 全球直腸癌分子診斷市場（依應用）

• 概述
• 依用途：吸引力分析
• 臨床診斷：趨勢與預測（2019-2031）
• 藥物篩檢：趨勢與預測（2019-2031）
• 研究：趨勢與預測（2019-2031）

第6章 區域分析

• 概述
• 全球直腸癌分子診斷市場（按地區）

7. 北美直腸癌分子診斷市場

• 概述
• 北美直腸癌分子診斷市場（按類型）
• 北美直腸癌分子診斷市場（依應用）
• 美國直腸癌分子診斷市場
• 墨西哥直腸癌分子診斷市場
• 加拿大直腸癌分子診斷市場

8. 歐洲直腸癌分子診斷市場

• 概述
• 歐洲直腸癌分子診斷市場（按類型）
• 歐洲直腸癌分子診斷市場（依應用）
• 德國直腸癌分子診斷市場
• 法國直腸癌分子診斷市場
• 西班牙直腸癌分子診斷市場
• 義大利直腸癌分子診斷市場
• 英國直腸癌分子診斷市場

9. 亞太直腸癌分子診斷市場

• 概述
• 亞太直腸癌分子診斷市場（按類型）
• 亞太直腸癌分子診斷市場（依應用）
• 日本直腸癌分子診斷市場
• 印度直腸癌分子診斷市場
• 中國直腸癌分子診斷市場
• 韓國直腸癌分子診斷市場
• 印尼直腸癌分子診斷市場

第10章世界其他地區直腸癌分子診斷市場

• 概述
• 世界其他地區直腸癌分子診斷市場（按類型）
• 世界其他地區直腸癌分子診斷市場（按應用）
• 中東直腸癌分子診斷市場
• 南美洲直腸癌分子診斷市場
• 非洲直腸癌分子診斷市場

第11章 競爭分析

• 產品系列分析
• 營運整合
• 波特五力分析
  • 競爭對手之間的競爭
  • 買方的議價能力
  • 供應商的議價能力
  • 替代品的威脅
  • 新進入者的威脅
• 市佔率分析

第12章：機會與策略分析

• 價值鏈分析
• 成長機會分析
  • 按類型分類的成長機會
  • 按應用分類的成長機會
• 全球直腸癌分子診斷市場的新趨勢
• 戰略分析
  • 新產品開發
  • 認證和許可
  • 合併、收購、協議、合作和合資企業

第13章 價值鏈主要企業的公司簡介

• Competitive Analysis
• Kingmed
• Geneis
• Unitedgene
• Yin Feng Gene
• Inmedi
• Amoydx
• Genetronhealth

第14章 附錄

• 圖表目錄
• 表格列表
• 調查方法
• 免責聲明
• 版權
• 簡稱和技術單位
• 關於我們
• 詢問

The future of the global molecular diagnosis of rectal cancer market looks promising with opportunities in the clinical diagnosis, drug screening, and research markets. The global molecular diagnosis of rectal cancer market is expected to grow with a CAGR of 11.5% from 2025 to 2031. The major drivers for this market are the rising prevalence of rectal cancer and demand for early detection and the growing adoption of personalized medicine and targeted treatment approaches.

• Lucintel forecasts that, within the type category, DNA sequencing will remain the largest segment over the forecast period.
• Within the application category, clinical diagnosis is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Molecular Diagnosis of Rectal Cancer Market

The molecular diagnosis of rectal cancer market is witnessing several emerging trends, with innovations in diagnostic techniques, personalized treatment options, and advancements in non-invasive testing methods. These trends are shaping the market's future and improving clinical outcomes.

• Rise of Liquid Biopsy Technologies: Liquid biopsy is increasingly being used for the molecular diagnosis of rectal cancer. It offers a non-invasive alternative to traditional tissue biopsy, allowing for the detection of tumor DNA in blood samples. This technology improves early detection and helps in monitoring treatment responses, enabling better patient management.
• Advancements in Next-Generation Sequencing (NGS): NGS has become a cornerstone of molecular diagnostics, enabling the detection of genetic mutations and alterations associated with rectal cancer. NGS allows for comprehensive genomic profiling, which aids in the early identification of cancer and the development of personalized treatment strategies.
• Growing Focus on Personalized Medicine: Personalized medicine is gaining momentum in the molecular diagnosis of rectal cancer. By identifying genetic mutations, healthcare providers can tailor treatments based on individual patient profiles. This approach ensures that patients receive the most effective therapies, improving their chances of survival and reducing unnecessary side effects
• Integration of Artificial Intelligence (AI) in Diagnostics: AI is playing a significant role in the molecular diagnosis of rectal cancer by analyzing large sets of patient data, including genetic, histopathological, and imaging data. AI tools can detect patterns that human clinicians might miss, enhancing diagnostic accuracy and providing more precise prognostic information.
• Increased Adoption of Point-of-Care Diagnostics: There is a growing interest in point-of-care diagnostics, which allows for faster molecular testing and quicker results. This trend is particularly relevant in developing countries where access to centralized diagnostic laboratories may be limited. Point-of-care technologies are helping make molecular diagnosis more accessible and timely.

These emerging trends are transforming the molecular diagnosis of rectal cancer by making detection earlier, more accurate, and less invasive. They are paving the way for more personalized treatment strategies and improving clinical outcomes for patients worldwide, enhancing the overall prognosis for rectal cancer.

Recent Developments in the Molecular Diagnosis of Rectal Cancer Market

The molecular diagnosis of rectal cancer is undergoing rapid development with advancements in diagnostic techniques, biomarkers, and treatment strategies. These developments are enhancing diagnostic accuracy and the ability to tailor treatments to individual patients.

• Introduction: Several key developments are shaping the molecular diagnosis of rectal cancer, including the rise of non-invasive diagnostic methods, better access to genomic testing, and integration of AI technologies. These developments are improving diagnostic capabilities and patient care in the field of rectal cancer.
• Advancement of Non-Invasive Testing: Non-invasive testing methods such as liquid biopsy and stool-based DNA testing are rapidly advancing. These technologies allow for early detection of rectal cancer with minimal patient discomfort, paving the way for more widespread screening and monitoring options, especially in underserved populations.
• Improved Genomic Profiling Techniques: Genomic profiling is evolving with the use of next-generation sequencing (NGS) to better identify specific mutations linked to rectal cancer. This has led to more precise diagnoses and the development of personalized therapies, improving treatment outcomes for patients.
• Artificial Intelligence in Diagnostics: AI is being incorporated into molecular diagnostics for rectal cancer, improving both the accuracy and efficiency of detection. AI can analyze genomic data, medical records, and imaging results to identify patterns indicative of early-stage rectal cancer, enabling quicker interventions and better prognosis.
• Emerging Biomarkers for Early Detection: Researchers are identifying new biomarkers specific to rectal cancer, which are improving early detection and prognostication. Biomarkers such as specific genetic mutations and circulating tumor DNA can help in determining the most effective treatment approaches and monitoring patient progress.
• Growth of Personalized Medicine: Personalized medicine is expanding within rectal cancer diagnostics. By analyzing a patient's genetic profile, clinicians can choose the most appropriate treatments, including targeted therapies, improving patient outcomes while minimizing the side effects of traditional treatments.

These key developments are advancing the molecular diagnosis of rectal cancer, making early detection more effective and treatment more personalized. As these technologies continue to evolve, they hold the potential to significantly improve patient outcomes and revolutionize cancer care globally.

Strategic Growth Opportunities in the Molecular Diagnosis of Rectal Cancer Market

The global molecular diagnosis of rectal cancer market offers significant growth opportunities across various applications, driven by advancements in diagnostics and increasing demand for personalized medicine.

• Early Detection Screening Programs: Early detection is a key growth opportunity, especially as molecular diagnostics improve. Governments and healthcare organizations are increasingly implementing screening programs to detect rectal cancer at early stages, where treatment options are more effective. This market segment is expanding as molecular tests become more accessible and affordable.
• Personalized Treatment Plans: Personalized treatment strategies, informed by molecular diagnostics, offer a significant growth opportunity. By using genetic and biomarker profiling, clinicians can tailor therapies that target specific mutations, improving treatment efficacy and patient outcomes. This approach is particularly important in rectal cancer, where treatment response varies.
• Point-of-Care Diagnostics in Developing Markets: There is an opportunity to expand point-of-care molecular diagnostic tools in developing countries, where access to centralized healthcare may be limited. These tools enable quicker diagnosis, allowing for faster treatment initiation, which can significantly improve survival rates.
• Integration of AI for Faster Diagnosis: AI offers significant growth opportunities in the molecular diagnosis of rectal cancer, especially in data analysis. By integrating AI with molecular diagnostic tools, healthcare providers can achieve quicker and more accurate results, leading to faster interventions and better outcomes for patients.
• Expanding Liquid Biopsy Technologies: Liquid biopsy is rapidly becoming a preferred method for non-invasive testing. This technology offers the ability to detect tumor DNA in blood, facilitating early diagnosis, monitoring, and treatment response evaluation. The expansion of liquid biopsy technologies is expected to significantly boost the molecular diagnosis market.

The molecular diagnosis of rectal cancer market is ripe with growth opportunities, driven by advancements in early detection, personalized medicine, and AI integration. As these technologies evolve, they promise to revolutionize cancer care, improving patient outcomes and increasing access to timely treatment.

Molecular Diagnosis of Rectal Cancer Market Driver and Challenges

The molecular diagnosis of rectal cancer is influenced by various drivers such as technological advancements, increased awareness, and improved healthcare access. However, challenges related to cost, regulatory hurdles, and market penetration need to be addressed for sustained growth in this field.

The factors responsible for driving the molecular diagnosis of rectal cancer market include:

1. Technological Advancements in Diagnostics: The continuous development of advanced diagnostic technologies such as next-generation sequencing (NGS) and liquid biopsy is driving market growth. These innovations enable more accurate, less invasive, and earlier detection of rectal cancer, improving patient outcomes and increasing the demand for molecular diagnostic tools.

2. Growing Demand for Personalized Medicine: With the shift toward personalized medicine, there is an increasing demand for molecular diagnostics to guide treatment decisions. By identifying specific biomarkers and genetic mutations, healthcare providers can tailor treatments to the individual, improving efficacy and reducing side effects, thereby enhancing market growth.

3. Rising Awareness of Rectal Cancer: As awareness of rectal cancer and its risks rises globally, patients are more proactive about screening and diagnosis. This is leading to greater adoption of molecular diagnostic techniques, particularly in countries with developed healthcare systems.

4. Government and Healthcare Initiatives: Governments and healthcare organizations are promoting early detection and screening programs for rectal cancer. Increased funding and support for molecular diagnostics in these initiatives are helping expand access to cutting-edge diagnostic tools, contributing to market growth.

5. Improvement in Healthcare Access: As healthcare access improves in developing regions, the adoption of molecular diagnostics is expected to increase. This will drive market growth by enabling more widespread use of advanced diagnostic techniques, which were previously limited to wealthier countries.

Challenges in the molecular diagnosis of rectal cancer market are:

1. High Cost of Molecular Diagnostics: The high cost of advanced molecular diagnostic techniques is a major barrier to market growth, especially in low- and middle-income countries. The cost of technologies such as NGS and liquid biopsy needs to decrease to make these tools more accessible and affordable for a wider population.

2. Regulatory Challenges: Regulatory approvals for new diagnostic tests can be slow and challenging, particularly for new technologies like liquid biopsy. Navigating these regulatory hurdles can delay the widespread adoption of new diagnostic methods.

3. Limited Awareness and Accessibility in Rural Areas: Despite advancements in technology, there is limited access to molecular diagnostics in rural and underserved regions. Lack of infrastructure and awareness about the importance of early rectal cancer detection poses a challenge to the growth of the market.

Technological advancements, personalized medicine, and government support are key drivers of the molecular diagnosis of rectal cancer market. However, challenges like high costs, regulatory hurdles, and limited access in rural areas need to be addressed to ensure broader adoption of these life-saving diagnostic tools.

List of Molecular Diagnosis of Rectal Cancer Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies molecular diagnosis of rectal cancer companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the molecular diagnosis of rectal cancer companies profiled in this report include-

• Kingmed
• Geneis
• Unitedgene
• Yin Feng Gene
• Inmedi
• Amoydx
• Genetronhealth

Molecular Diagnosis of Rectal Cancer Market by Segment

The study includes a forecast for the global molecular diagnosis of rectal cancer market by type, application, and region.

Molecular Diagnosis of Rectal Cancer Market by Type [Value from 2019 to 2031]:

• PCR
• FISH
• DNA Sequencing
• Gene Chip

Molecular Diagnosis of Rectal Cancer Market by Application [Value from 2019 to 2031]:

• Clinical Diagnosis
• Drug Screening
• Research

Molecular Diagnosis of Rectal Cancer Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Molecular Diagnosis of Rectal Cancer Market

The global market for the molecular diagnosis of rectal cancer is evolving rapidly with advancements in genetic testing, biomarker discovery, and imaging technologies. These innovations are transforming early detection, prognosis assessment, and personalized treatment strategies for rectal cancer. Countries like the United States, China, Germany, India, and Japan are leading these developments, focusing on improving diagnostic accuracy and patient outcomes through cutting-edge molecular techniques.

• United States: In the United States, the molecular diagnosis of rectal cancer is benefiting from significant advancements in genomic testing and liquid biopsy technologies. Major institutions and companies are integrating next-generation sequencing (NGS) and artificial intelligence to enhance detection accuracy and predict patient responses to treatment. The U.S. market also sees increasing use of comprehensive genetic profiling to tailor personalized therapies, helping in better treatment planning and outcome prediction for patients with rectal cancer.
• China: China is experiencing rapid growth in the molecular diagnosis of rectal cancer, largely driven by the country's investment in advanced healthcare technologies and research. The Chinese market is seeing increased adoption of molecular diagnostic tools like PCR, NGS, and liquid biopsy, enabling earlier and more accurate detection of rectal cancer. Additionally, there is a focus on developing cost-effective solutions to make advanced diagnostics accessible across urban and rural areas, aiming to improve early diagnosis and survival rates.
• Germany: In Germany, the molecular diagnosis of rectal cancer is advancing with the integration of precision medicine and genetic testing into clinical practice. Key advancements include the use of molecular markers to guide treatment decisions and predict patient outcomes. Germany's focus on personalized healthcare is driving the adoption of liquid biopsy and genetic profiling, improving early detection and enabling more effective management of rectal cancer. Germany is also a hub for research into novel biomarkers that could further refine diagnostic accuracy.
• India: India is focusing on improving the molecular diagnosis of rectal cancer through increased access to affordable genomic testing and advanced imaging technologies. Companies and hospitals are expanding their use of NGS and PCR for early detection and monitoring of rectal cancer. India's healthcare system is embracing molecular diagnostics to enhance personalized treatment plans and improve patient outcomes, although challenges remain in accessibility and cost-effectiveness in rural areas.
• Japan: Japan has made significant progress in the molecular diagnosis of rectal cancer, with a strong emphasis on advanced diagnostic technologies like NGS and liquid biopsy. The Japanese healthcare system is increasingly adopting molecular profiling for personalized treatment regimens, including targeted therapies. Research institutions are also investigating novel biomarkers to improve the detection of early-stage rectal cancer, aiming to enhance early intervention and improve survival rates through timely diagnosis.

Features of the Global Molecular Diagnosis of Rectal Cancer Market

• Market Size Estimates: Molecular diagnosis of rectal cancer market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Molecular diagnosis of rectal cancer market size by type, application, and region in terms of value ($B).
• Regional Analysis: Molecular diagnosis of rectal cancer market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the molecular diagnosis of rectal cancer market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the molecular diagnosis of rectal cancer market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the molecular diagnosis of rectal cancer market by type (PCR, FISH, DNA sequencing, and gene chip), application (clinical diagnosis, drug screening, and research), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Molecular Diagnosis of Rectal Cancer Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 PCR: Trends and Forecast (2019-2031)
• 4.4 FISH: Trends and Forecast (2019-2031)
• 4.5 DNA Sequencing: Trends and Forecast (2019-2031)
• 4.6 Gene Chip: Trends and Forecast (2019-2031)

5. Global Molecular Diagnosis of Rectal Cancer Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Clinical Diagnosis: Trends and Forecast (2019-2031)
• 5.4 Drug Screening: Trends and Forecast (2019-2031)
• 5.5 Research: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Molecular Diagnosis of Rectal Cancer Market by Region

7. North American Molecular Diagnosis of Rectal Cancer Market

• 7.1 Overview
• 7.2 North American Molecular Diagnosis of Rectal Cancer Market by type
• 7.3 North American Molecular Diagnosis of Rectal Cancer Market by application
• 7.4 United States Molecular Diagnosis of Rectal Cancer Market
• 7.5 Mexican Molecular Diagnosis of Rectal Cancer Market
• 7.6 Canadian Molecular Diagnosis of Rectal Cancer Market

8. European Molecular Diagnosis of Rectal Cancer Market

• 8.1 Overview
• 8.2 European Molecular Diagnosis of Rectal Cancer Market by type
• 8.3 European Molecular Diagnosis of Rectal Cancer Market by application
• 8.4 German Molecular Diagnosis of Rectal Cancer Market
• 8.5 French Molecular Diagnosis of Rectal Cancer Market
• 8.6 Spanish Molecular Diagnosis of Rectal Cancer Market
• 8.7 Italian Molecular Diagnosis of Rectal Cancer Market
• 8.8 United Kingdom Molecular Diagnosis of Rectal Cancer Market

9. APAC Molecular Diagnosis of Rectal Cancer Market

• 9.1 Overview
• 9.2 APAC Molecular Diagnosis of Rectal Cancer Market by type
• 9.3 APAC Molecular Diagnosis of Rectal Cancer Market by application
• 9.4 Japanese Molecular Diagnosis of Rectal Cancer Market
• 9.5 Indian Molecular Diagnosis of Rectal Cancer Market
• 9.6 Chinese Molecular Diagnosis of Rectal Cancer Market
• 9.7 South Korean Molecular Diagnosis of Rectal Cancer Market
• 9.8 Indonesian Molecular Diagnosis of Rectal Cancer Market

10. ROW Molecular Diagnosis of Rectal Cancer Market

• 10.1 Overview
• 10.2 ROW Molecular Diagnosis of Rectal Cancer Market by type
• 10.3 ROW Molecular Diagnosis of Rectal Cancer Market by application
• 10.4 Middle Eastern Molecular Diagnosis of Rectal Cancer Market
• 10.5 South American Molecular Diagnosis of Rectal Cancer Market
• 10.6 African Molecular Diagnosis of Rectal Cancer Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Molecular Diagnosis of Rectal Cancer Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Kingmed
  • Company Overview
  • Molecular Diagnosis of Rectal Cancer Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Geneis
  • Company Overview
  • Molecular Diagnosis of Rectal Cancer Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Unitedgene
  • Company Overview
  • Molecular Diagnosis of Rectal Cancer Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Yin Feng Gene
  • Company Overview
  • Molecular Diagnosis of Rectal Cancer Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Inmedi
  • Company Overview
  • Molecular Diagnosis of Rectal Cancer Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Amoydx
  • Company Overview
  • Molecular Diagnosis of Rectal Cancer Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Genetronhealth
  • Company Overview
  • Molecular Diagnosis of Rectal Cancer Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us

List of Figures

• Figure 1.1: Trends and Forecast for the Global Molecular Diagnosis of Rectal Cancer Market
• Figure 2.1: Usage of Molecular Diagnosis of Rectal Cancer Market
• Figure 2.2: Classification of the Global Molecular Diagnosis of Rectal Cancer Market
• Figure 2.3: Supply Chain of the Global Molecular Diagnosis of Rectal Cancer Market
• Figure 3.1: Driver and Challenges of the Molecular Diagnosis of Rectal Cancer Market
• Figure 3.2: PESTLE Analysis
• Figure 3.3: Patent Analysis
• Figure 3.4: Regulatory Environment
• Figure 4.1: Global Molecular Diagnosis of Rectal Cancer Market by Type in 2019, 2024, and 2031
• Figure 4.2: Trends of the Global Molecular Diagnosis of Rectal Cancer Market ($B) by Type
• Figure 4.3: Forecast for the Global Molecular Diagnosis of Rectal Cancer Market ($B) by Type
• Figure 4.4: Trends and Forecast for PCR in the Global Molecular Diagnosis of Rectal Cancer Market (2019-2031)
• Figure 4.5: Trends and Forecast for FISH in the Global Molecular Diagnosis of Rectal Cancer Market (2019-2031)
• Figure 4.6: Trends and Forecast for DNA Sequencing in the Global Molecular Diagnosis of Rectal Cancer Market (2019-2031)
• Figure 4.7: Trends and Forecast for Gene Chip in the Global Molecular Diagnosis of Rectal Cancer Market (2019-2031)
• Figure 5.1: Global Molecular Diagnosis of Rectal Cancer Market by Application in 2019, 2024, and 2031
• Figure 5.2: Trends of the Global Molecular Diagnosis of Rectal Cancer Market ($B) by Application
• Figure 5.3: Forecast for the Global Molecular Diagnosis of Rectal Cancer Market ($B) by Application
• Figure 5.4: Trends and Forecast for Clinical Diagnosis in the Global Molecular Diagnosis of Rectal Cancer Market (2019-2031)
• Figure 5.5: Trends and Forecast for Drug Screening in the Global Molecular Diagnosis of Rectal Cancer Market (2019-2031)
• Figure 5.6: Trends and Forecast for Research in the Global Molecular Diagnosis of Rectal Cancer Market (2019-2031)
• Figure 6.1: Trends of the Global Molecular Diagnosis of Rectal Cancer Market ($B) by Region (2019-2024)
• Figure 6.2: Forecast for the Global Molecular Diagnosis of Rectal Cancer Market ($B) by Region (2025-2031)
• Figure 7.1: North American Molecular Diagnosis of Rectal Cancer Market by type in 2019, 2024, and 2031
• Figure 7.2: Trends of the North American Molecular Diagnosis of Rectal Cancer Market ($B) by type (2019-2024)
• Figure 7.3: Forecast for the North American Molecular Diagnosis of Rectal Cancer Market ($B) by type (2025-2031)
• Figure 7.4: North American Molecular Diagnosis of Rectal Cancer Market by application in 2019, 2024, and 2031
• Figure 7.5: Trends of the North American Molecular Diagnosis of Rectal Cancer Market ($B) by application (2019-2024)
• Figure 7.6: Forecast for the North American Molecular Diagnosis of Rectal Cancer Market ($B) by application (2025-2031)
• Figure 7.7: Trends and Forecast for the United States Molecular Diagnosis of Rectal Cancer Market ($B) (2019-2031)
• Figure 7.8: Trends and Forecast for the Mexican Molecular Diagnosis of Rectal Cancer Market ($B) (2019-2031)
• Figure 7.9: Trends and Forecast for the Canadian Molecular Diagnosis of Rectal Cancer Market ($B) (2019-2031)
• Figure 8.1: European Molecular Diagnosis of Rectal Cancer Market by type in 2019, 2024, and 2031
• Figure 8.2: Trends of the European Molecular Diagnosis of Rectal Cancer Market ($B) by type (2019-2024)
• Figure 8.3: Forecast for the European Molecular Diagnosis of Rectal Cancer Market ($B) by type (2025-2031)
• Figure 8.4: European Molecular Diagnosis of Rectal Cancer Market by application in 2019, 2024, and 2031
• Figure 8.5: Trends of the European Molecular Diagnosis of Rectal Cancer Market ($B) by application (2019-2024)
• Figure 8.6: Forecast for the European Molecular Diagnosis of Rectal Cancer Market ($B) by application (2025-2031)
• Figure 8.7: Trends and Forecast for the German Molecular Diagnosis of Rectal Cancer Market ($B) (2019-2031)
• Figure 8.8: Trends and Forecast for the French Molecular Diagnosis of Rectal Cancer Market ($B) (2019-2031)
• Figure 8.9: Trends and Forecast for the Spanish Molecular Diagnosis of Rectal Cancer Market ($B) (2019-2031)
• Figure 8.10: Trends and Forecast for the Italian Molecular Diagnosis of Rectal Cancer Market ($B) (2019-2031)
• Figure 8.11: Trends and Forecast for the United Kingdom Molecular Diagnosis of Rectal Cancer Market ($B) (2019-2031)
• Figure 9.1: APAC Molecular Diagnosis of Rectal Cancer Market by type in 2019, 2024, and 2031
• Figure 9.2: Trends of the APAC Molecular Diagnosis of Rectal Cancer Market ($B) by type (2019-2024)
• Figure 9.3: Forecast for the APAC Molecular Diagnosis of Rectal Cancer Market ($B) by type (2025-2031)
• Figure 9.4: APAC Molecular Diagnosis of Rectal Cancer Market by application in 2019, 2024, and 2031
• Figure 9.5: Trends of the APAC Molecular Diagnosis of Rectal Cancer Market ($B) by application (2019-2024)
• Figure 9.6: Forecast for the APAC Molecular Diagnosis of Rectal Cancer Market ($B) by application (2025-2031)
• Figure 9.7: Trends and Forecast for the Japanese Molecular Diagnosis of Rectal Cancer Market ($B) (2019-2031)
• Figure 9.8: Trends and Forecast for the Indian Molecular Diagnosis of Rectal Cancer Market ($B) (2019-2031)
• Figure 9.9: Trends and Forecast for the Chinese Molecular Diagnosis of Rectal Cancer Market ($B) (2019-2031)
• Figure 9.10: Trends and Forecast for the South Korean Molecular Diagnosis of Rectal Cancer Market ($B) (2019-2031)
• Figure 9.11: Trends and Forecast for the Indonesian Molecular Diagnosis of Rectal Cancer Market ($B) (2019-2031)
• Figure 10.1: ROW Molecular Diagnosis of Rectal Cancer Market by type in 2019, 2024, and 2031
• Figure 10.2: Trends of the ROW Molecular Diagnosis of Rectal Cancer Market ($B) by type (2019-2024)
• Figure 10.3: Forecast for the ROW Molecular Diagnosis of Rectal Cancer Market ($B) by type (2025-2031)
• Figure 10.4: ROW Molecular Diagnosis of Rectal Cancer Market by application in 2019, 2024, and 2031
• Figure 10.5: Trends of the ROW Molecular Diagnosis of Rectal Cancer Market ($B) by application (2019-2024)
• Figure 10.6: Forecast for the ROW Molecular Diagnosis of Rectal Cancer Market ($B) by application (2025-2031)
• Figure 10.7: Trends and Forecast for the Middle Eastern Molecular Diagnosis of Rectal Cancer Market ($B) (2019-2031)
• Figure 10.8: Trends and Forecast for the South American Molecular Diagnosis of Rectal Cancer Market ($B) (2019-2031)
• Figure 10.9: Trends and Forecast for the African Molecular Diagnosis of Rectal Cancer Market ($B) (2019-2031)
• Figure 11.1: Porter's Five Forces Analysis of the Global Molecular Diagnosis of Rectal Cancer Market
• Figure 11.2: Market Share (%) of Top Players in the Global Molecular Diagnosis of Rectal Cancer Market (2024)
• Figure 12.1: Growth Opportunities for the Global Molecular Diagnosis of Rectal Cancer Market by Type
• Figure 12.2: Growth Opportunities for the Global Molecular Diagnosis of Rectal Cancer Market by Application
• Figure 12.3: Growth Opportunities for the Global Molecular Diagnosis of Rectal Cancer Market by Region
• Figure 12.4: Emerging Trends in the Global Molecular Diagnosis of Rectal Cancer Market

List of Tables

• Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Molecular Diagnosis of Rectal Cancer Market by Type and Application
• Table 1.2: Attractiveness Analysis for the Molecular Diagnosis of Rectal Cancer Market by Region
• Table 1.3: Global Molecular Diagnosis of Rectal Cancer Market Parameters and Attributes
• Table 3.1: Trends of the Global Molecular Diagnosis of Rectal Cancer Market (2019-2024)
• Table 3.2: Forecast for the Global Molecular Diagnosis of Rectal Cancer Market (2025-2031)
• Table 4.1: Attractiveness Analysis for the Global Molecular Diagnosis of Rectal Cancer Market by Type
• Table 4.2: Market Size and CAGR of Various Type in the Global Molecular Diagnosis of Rectal Cancer Market (2019-2024)
• Table 4.3: Market Size and CAGR of Various Type in the Global Molecular Diagnosis of Rectal Cancer Market (2025-2031)
• Table 4.4: Trends of PCR in the Global Molecular Diagnosis of Rectal Cancer Market (2019-2024)
• Table 4.5: Forecast for PCR in the Global Molecular Diagnosis of Rectal Cancer Market (2025-2031)
• Table 4.6: Trends of FISH in the Global Molecular Diagnosis of Rectal Cancer Market (2019-2024)
• Table 4.7: Forecast for FISH in the Global Molecular Diagnosis of Rectal Cancer Market (2025-2031)
• Table 4.8: Trends of DNA Sequencing in the Global Molecular Diagnosis of Rectal Cancer Market (2019-2024)
• Table 4.9: Forecast for DNA Sequencing in the Global Molecular Diagnosis of Rectal Cancer Market (2025-2031)
• Table 4.10: Trends of Gene Chip in the Global Molecular Diagnosis of Rectal Cancer Market (2019-2024)
• Table 4.11: Forecast for Gene Chip in the Global Molecular Diagnosis of Rectal Cancer Market (2025-2031)
• Table 5.1: Attractiveness Analysis for the Global Molecular Diagnosis of Rectal Cancer Market by Application
• Table 5.2: Market Size and CAGR of Various Application in the Global Molecular Diagnosis of Rectal Cancer Market (2019-2024)
• Table 5.3: Market Size and CAGR of Various Application in the Global Molecular Diagnosis of Rectal Cancer Market (2025-2031)
• Table 5.4: Trends of Clinical Diagnosis in the Global Molecular Diagnosis of Rectal Cancer Market (2019-2024)
• Table 5.5: Forecast for Clinical Diagnosis in the Global Molecular Diagnosis of Rectal Cancer Market (2025-2031)
• Table 5.6: Trends of Drug Screening in the Global Molecular Diagnosis of Rectal Cancer Market (2019-2024)
• Table 5.7: Forecast for Drug Screening in the Global Molecular Diagnosis of Rectal Cancer Market (2025-2031)
• Table 5.8: Trends of Research in the Global Molecular Diagnosis of Rectal Cancer Market (2019-2024)
• Table 5.9: Forecast for Research in the Global Molecular Diagnosis of Rectal Cancer Market (2025-2031)
• Table 6.1: Market Size and CAGR of Various Regions in the Global Molecular Diagnosis of Rectal Cancer Market (2019-2024)
• Table 6.2: Market Size and CAGR of Various Regions in the Global Molecular Diagnosis of Rectal Cancer Market (2025-2031)
• Table 7.1: Trends of the North American Molecular Diagnosis of Rectal Cancer Market (2019-2024)
• Table 7.2: Forecast for the North American Molecular Diagnosis of Rectal Cancer Market (2025-2031)
• Table 7.3: Market Size and CAGR of Various type in the North American Molecular Diagnosis of Rectal Cancer Market (2019-2024)
• Table 7.4: Market Size and CAGR of Various type in the North American Molecular Diagnosis of Rectal Cancer Market (2025-2031)
• Table 7.5: Market Size and CAGR of Various application in the North American Molecular Diagnosis of Rectal Cancer Market (2019-2024)
• Table 7.6: Market Size and CAGR of Various application in the North American Molecular Diagnosis of Rectal Cancer Market (2025-2031)
• Table 7.7: Trends and Forecast for the United States Molecular Diagnosis of Rectal Cancer Market (2019-2031)
• Table 7.8: Trends and Forecast for the Mexican Molecular Diagnosis of Rectal Cancer Market (2019-2031)
• Table 7.9: Trends and Forecast for the Canadian Molecular Diagnosis of Rectal Cancer Market (2019-2031)
• Table 8.1: Trends of the European Molecular Diagnosis of Rectal Cancer Market (2019-2024)
• Table 8.2: Forecast for the European Molecular Diagnosis of Rectal Cancer Market (2025-2031)
• Table 8.3: Market Size and CAGR of Various type in the European Molecular Diagnosis of Rectal Cancer Market (2019-2024)
• Table 8.4: Market Size and CAGR of Various type in the European Molecular Diagnosis of Rectal Cancer Market (2025-2031)
• Table 8.5: Market Size and CAGR of Various application in the European Molecular Diagnosis of Rectal Cancer Market (2019-2024)
• Table 8.6: Market Size and CAGR of Various application in the European Molecular Diagnosis of Rectal Cancer Market (2025-2031)
• Table 8.7: Trends and Forecast for the German Molecular Diagnosis of Rectal Cancer Market (2019-2031)
• Table 8.8: Trends and Forecast for the French Molecular Diagnosis of Rectal Cancer Market (2019-2031)
• Table 8.9: Trends and Forecast for the Spanish Molecular Diagnosis of Rectal Cancer Market (2019-2031)
• Table 8.10: Trends and Forecast for the Italian Molecular Diagnosis of Rectal Cancer Market (2019-2031)
• Table 8.11: Trends and Forecast for the United Kingdom Molecular Diagnosis of Rectal Cancer Market (2019-2031)
• Table 9.1: Trends of the APAC Molecular Diagnosis of Rectal Cancer Market (2019-2024)
• Table 9.2: Forecast for the APAC Molecular Diagnosis of Rectal Cancer Market (2025-2031)
• Table 9.3: Market Size and CAGR of Various type in the APAC Molecular Diagnosis of Rectal Cancer Market (2019-2024)
• Table 9.4: Market Size and CAGR of Various type in the APAC Molecular Diagnosis of Rectal Cancer Market (2025-2031)
• Table 9.5: Market Size and CAGR of Various application in the APAC Molecular Diagnosis of Rectal Cancer Market (2019-2024)
• Table 9.6: Market Size and CAGR of Various application in the APAC Molecular Diagnosis of Rectal Cancer Market (2025-2031)
• Table 9.7: Trends and Forecast for the Japanese Molecular Diagnosis of Rectal Cancer Market (2019-2031)
• Table 9.8: Trends and Forecast for the Indian Molecular Diagnosis of Rectal Cancer Market (2019-2031)
• Table 9.9: Trends and Forecast for the Chinese Molecular Diagnosis of Rectal Cancer Market (2019-2031)
• Table 9.10: Trends and Forecast for the South Korean Molecular Diagnosis of Rectal Cancer Market (2019-2031)
• Table 9.11: Trends and Forecast for the Indonesian Molecular Diagnosis of Rectal Cancer Market (2019-2031)
• Table 10.1: Trends of the ROW Molecular Diagnosis of Rectal Cancer Market (2019-2024)
• Table 10.2: Forecast for the ROW Molecular Diagnosis of Rectal Cancer Market (2025-2031)
• Table 10.3: Market Size and CAGR of Various type in the ROW Molecular Diagnosis of Rectal Cancer Market (2019-2024)
• Table 10.4: Market Size and CAGR of Various type in the ROW Molecular Diagnosis of Rectal Cancer Market (2025-2031)
• Table 10.5: Market Size and CAGR of Various application in the ROW Molecular Diagnosis of Rectal Cancer Market (2019-2024)
• Table 10.6: Market Size and CAGR of Various application in the ROW Molecular Diagnosis of Rectal Cancer Market (2025-2031)
• Table 10.7: Trends and Forecast for the Middle Eastern Molecular Diagnosis of Rectal Cancer Market (2019-2031)
• Table 10.8: Trends and Forecast for the South American Molecular Diagnosis of Rectal Cancer Market (2019-2031)
• Table 10.9: Trends and Forecast for the African Molecular Diagnosis of Rectal Cancer Market (2019-2031)
• Table 11.1: Product Mapping of Molecular Diagnosis of Rectal Cancer Suppliers Based on Segments
• Table 11.2: Operational Integration of Molecular Diagnosis of Rectal Cancer Manufacturers
• Table 11.3: Rankings of Suppliers Based on Molecular Diagnosis of Rectal Cancer Revenue
• Table 12.1: New Product Launches by Major Molecular Diagnosis of Rectal Cancer Producers (2019-2024)
• Table 12.2: Certification Acquired by Major Competitor in the Global Molecular Diagnosis of Rectal Cancer Market